Skip to content

8-KAccepted Nov 12, 4:16 PM ET

Atrium Therapeutics, Inc.: reports quarter ended Sep 30, 2026 results

RNAAtrium Therapeutics, Inc.

Accepted (ET)

4:16 PM

Nov 12, 2026

Filed

Nov 12, 2026

Documents

13

Size

252.4 KB

Summary

Atrium Therapeutics, Inc.: reports quarter ended Sep 30, 2026 results

Updated

What happened Atrium Therapeutics, Inc. announced its financial results for the quarter ended Sep 30, 2026 on Nov 12, 2026. The company furnished the full text of the press release issued in connection with the announcement as Exhibit 99.1 to the Current Report on Form 8-K.

Key details

  • The Form 8-K reports Item 2.02: results of operations and financial condition.
  • The announcement date is Nov 12, 2026 and the quarter covered is the period ended Sep 30, 2026.
  • The press release is furnished as Exhibit 99.1 to the Form 8-K.

Why it may matter Item 2.02 covers results of operations and financial condition, i.e., the company announced its financial results for the quarter ended Sep 30, 2026. The filing does not show why the insider traded or why the company acted.

AI-written summary · check the filing